NewAmsterdam Pharma Company (NAMS) has provided an announcement.
Sander Slootweg has stepped down from the board of NewAmsterdam Pharma Company N.V., effective immediately, with no disagreements cited. Concurrently, the board welcomed Wouter Joustra and Mark C. McKenna as temporary non-executive directors, both meeting independent director requirements. Joustra brings experience from Forbion and European capital markets, while McKenna offers expertise from founding Mirador Therapeutics and prior executive roles in the pharmaceutical industry. Their appointments will be formalized at the upcoming shareholder meeting, with McKenna also joining the audit and compensation committees.
For a thorough assessment of NAMS stock, go to TipRanks’ Stock Analysis page.
